Table 2.
Immunogenicity of D1701-V-RabG application by different routes
| Route | Days after prime immunizationa |
No. of seroconverted/total no. of mice |
No. of survivors/total no. (%) | MTD (days) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| d7 | d14 | d21 | d28 | d35 | d42 | d7 | d14 | d21 | |||
| i.m. | 116 (75–125)b | 75 | 126 (75–375) | 171 (75–625) | 125 | 125 | 7/7 | 7/7 | 7/7 | 6/7 (86) | 14.0 |
| i.n. | 1 (0.1–15) | 1 (0.1–15) | 34 (15–125) | 159 (75–375) | 157 (125–625) | 184 (125–625) | 1/7 | 1/7 | 7/7 | 7/7 (100) | |
| i.v. | 81 (75–125) | 136 (75–375) | 108 (75–125) | 148 (75–375) | 125 | 80 (25–125) | 7/7 | 7/7 | 7/7 | 5/7 (71) | 15.0 |
| i.p. | 74 (25–125) | 117 (75–375) | 148 (75–625) | 136 (75–375) | 171 (125–375) | 116 (75–125) | 7/7 | 7/7 | 7/7 | 5/7 (71) | 13.5 |
| i.d. | 12 (1–75) | 30 (5–75) | 41 (15–75) | 62 (15–375) | 51 (25–125) | 51 (25–125) | 5/6 | 6/6 | 6/6 | 3/6 (50) | 11.7 |
| s.c. | 1 (0.1–15) | 3 (0.1–25) | 74 (25–125) | 64 (25–75) | 59 (25–125) | 47 (25–75) | 2/7 | 5/7 | 7/7 | 3/7 (43) | 12.5 |
| Oral | 0 (0.1–25) | 1 (0.1–75) | 26 (3–75) | 81 (15–375) | 164 (125–625) | 127 (75–375) | 1/7 | 2/7 | 7/7 | 5/7 (71) | 14.0 |
| PBS | <1 | <1 | <1 | <1 | <1 | <1 | 0/7 | 0/7 | 0/7 | 0/7 (0 ) | 8.3 |
a
Prime immunization at day 0, first boost at day 15, second boost at day 28, and challenge at day 49.
b
VNA titer in IU/ml: GMT (range).